Lower rates of hypoglycaemia with Ryzodeg compared to insulin aspart-Novo Nordisk

Data presented at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with Type 2 Diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg compared to biphasic insulin aspart 30, both administered twice-daily. Ryzodeg is the first combination of two distinct insulin analogues, Tresiba (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid (insulin aspart), in the ratio of 70% and 30%, in one pen for people with Type 2 Diabetes.